Treatment of Hyperpigmentation skin on Macular Amyloidosis patient with using two different types of lasers

Comparison of the efficacy of laser Q-switch 1064 ND:YAGR and erbium laser on the Hyperpigmentation of Macular Amyloidosis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20080901001159N23

Enrollment

Registered

2019-05-25

Start date

2014-03-21

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular amyloid. Amyloidosis of skin

Interventions

Intervention 1: Region of laser Q-switch Nd:YAG, 1064 nanometer: On the one side of the macular or (partA) , three sessions with four weeks intervals will be treated with with laser Q-switch N

Eligibility

Sex/Gender

All

Age

16 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age more than 16 and less than 60 Skin phenotype between 3-5 lack of acute infection in part of body which is under laser treatment Lack of inheritance and hormonal or malignant skin diseases

Exclusion criteria

Exclusion criteria: Using any drug related to decreasing pigment during last 2 weeks Laser therapy in order to treat macular during last 1 month No Solarium during last month No pregnancy and breastfeeding.

Design outcomes

Primary

Measure	Time frame
Melanin Index. Timepoint: Before and after laser therapy. Method of measurement: Multi Probe adaptor.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Zolghadr Elizei

Skin and Stem cell Research Center of Tehran University of Medical Sciences

saraz85182@hotmail.com+98 21 2220 1710

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 28, 2026